Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 8/20 | 0.43 |
| ▸ | JAK3 | P52333 | 8/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 7/20 | 0.35 |
| ▸ | CHUK | O15111 | 7/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12342128 | 0.92 | JAK2 (0.42) | JAK2JAK3JAK1TYK2IKBKB | |
| SCHEMBL12342116 | 0.89 | JAK2 (0.42) | JAK2JAK3JAK1TYK2IKBKB | |
| SCHEMBL2767255 | 0.89 | JAK2 (0.44) | JAK2JAK3JAK1TYK2IKBKB | |
| SCHEMBL12342124 | 0.88 | JAK2 (0.40) | JAK2JAK3JAK1TYK2IKBKB | |
| SCHEMBL12342146 | 0.86 | JAK2 (0.57) | JAK2JAK3JAK1TYK2IKBKB | |
| SCHEMBL12342148 | 0.86 | JAK2 (0.57) | JAK2JAK3JAK1TYK2IKBKB | |
| SCHEMBL12342140 | 0.86 | JAK2 (0.52) | JAK2JAK3JAK1TYK2IKBKB | |
| SCHEMBL12342127 | 0.85 | JAK2 (0.43) | JAK2JAK3JAK1TYK2IKBKB | |
| SCHEMBL12342150 | 0.85 | JAK2 (0.38) | JAK2JAK3JAK1TYK2IKBKB | |
| SCHEMBL12342126 | 0.84 | JAK2 (0.40) | JAK2JAK3JAK1TYK2IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268855-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-7737279-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | IL1R1, IDO1, TLR1 | JAK2 681/4885JAK3 1250/4885JAK1 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.